{"id":966553,"date":"2026-05-25T11:08:21","date_gmt":"2026-05-25T15:08:21","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/immunitybio-ibrx-facing-lawsuit-after-fda-flags-misleading-cancer-claims-shares-plunge-21-2b-market-cap-lost-hbss-3\/"},"modified":"2026-05-25T11:08:21","modified_gmt":"2026-05-25T15:08:21","slug":"immunitybio-ibrx-facing-lawsuit-after-fda-flags-misleading-cancer-claims-shares-plunge-21-2b-market-cap-lost-hbss-3","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/immunitybio-ibrx-facing-lawsuit-after-fda-flags-misleading-cancer-claims-shares-plunge-21-2b-market-cap-lost-hbss-3\/","title":{"rendered":"ImmunityBio (IBRX) Facing Lawsuit After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost — HBSS"},"content":{"rendered":"

\nIBRX Investors with Losses Encouraged to Contact the Firm Before May 26th Deadline
\n<\/h2>\n
\n

SAN FRANCISCO, May 25, 2026 (GLOBE NEWSWIRE) — ImmunityBio, Inc. (NASDAQ: IBRX)<\/strong> faces a securities class action lawsuit which seeks to represent investors who purchased or otherwise acquired ImmunityBio securities between January 19, 2026 and March 24, 2026.<\/p>\n

The lawsuit follows news that the FDA sent a warning letter to the company concerning claims made by its executive chairman and Chief Scientific and Medical Officer (Dr. Patrick Soon-Shiong) regarding ImmunityBio\u2019s lead biologic product (Anktiva), which the FDA said were misleading efficacy claims.<\/p>\n

This news drove the price of ImmunityBio shares down over 21% on March 24, 2026.<\/p>\n

The developments have prompted national shareholders rights firm Hagens Berman to investigate claims that ImmunityBio violated the federal securities laws.<\/p>\n

The firm urges investors in ImmunityBio who suffered significant losses to submit your losses now<\/a>. The firm also encourages witnesses who may be able to assist in the investigation to contact its attorneys.<\/p>\n

\n DEEP DIVE ANALYIS: <\/strong>Visit Hagens Berman\u2019s dedicated IBRX case page: www.hbsslaw.com\/cases\/immunitybio<\/strong><\/a>, <\/strong>or view our latest video summary of the allegations: https:\/\/youtu.be\/e1pGV9KiS8U<\/strong><\/a><\/p>\n\n\n\n\n
\n Class Period: <\/strong>Jan. 19, 2026 \u2013 Mar. 24, 2026
Lead Plaintiff Deadline: <\/strong>May 26, 2026
Visit:<\/strong>www.hbsslaw.com\/investor-fraud\/ibrx<\/a><\/td>\n<\/tr>\n
\n Contact the Firm Now:<\/strong>\n <\/td>\n\n IBRX@hbsslaw.com<\/a>
\n
\n 844-916-0895<\/strong>\n <\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n<\/table>\n

\n ImmunityBio, Inc. (IBRX) Securities Class Action: <\/strong>\n <\/p>\n

ImmunityBio is a biotechnology company focused on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient\u2019s immune system and deliver durable protection against cancer and infectious diseases.<\/p>\n

The company\u2019s Anktiva is an FDA-approved immunotherapy used with Bacillus Calmette-Gu\u00e9rin (\u201cBCG\u201d) to treat non-muscle invasive bladder cancer (\u201cNMIBC\u201d).<\/p>\n

The lawsuit is focused on the propriety of ImmunityBio\u2019s claims about Anktiva\u2019s efficacy for treating other forms of cancer.<\/p>\n

On January 19, 2026, a direct-to-consumer podcast (\u201cIs the FDA BLOCKING Life Saving Cancer Treatments?\u201d) aired, featuring Soon-Shiong. During the podcast, he said in part that, while Anktiva is approved for bladder cancer, \u201cit actually can treat all cancers.\u201d Soon-Shiong made other questionable claims about Anktiva, which together were flagged by the FDA as misleading.<\/p>\n

On March 24, 2026, the financial press reported that the FDA sent a warning letter to ImmunityBio over claims made in the podcast and a TV ad. The warning letter states the \u201cFDA has determined that the TV ad and podcast are false or misleading.\u201d The FDA explained, \u201cthe promotional materials create the misleading impression that Anktiva, a treatment for a certain type of bladder cancer, can cure and even prevent all cancer.\u201d<\/p>\n

In addition, the FDA warned that \u201cthe representations in the TV ad and podcast misleadingly suggest that Anktiva will allow all NIMBC patients treated with Anktiva to be cancer-free for the long term, when this has not been demonstrated\u201d and \u201cwe are not aware of data that support the efficacy claims and representations that Anktiva can \u2018cure\u2019 cancer.\u201d<\/p>\n

The FDA also said ImmunityBio\u2019s promotional materials were misleading because \u201cthey fail to provide material information regarding Anktiva\u2019s full FDA-approved indication.\u201d<\/p>\n

Lastly, the FDA warned that ImmunityBio\u2019s \u201cconsistent and pervasive misleading efficacy claims and representations presented across promotional materials on different platforms are especially concerning from a public health perspective, given they grossly misrepresent the benefits of Anktiva.\u201d<\/p>\n

This news drove the price of ImmunityBio shares down over 21% on March 24, 2026, erasing nearly $2 billion of the company\u2019s market capitalization.<\/p>\n

\u201cWe\u2019re investigating claims that ImmunityBio intentionally misled investors about Anktiva efficacy and indications,\u201d said Reed Kathrein, the Hagens Berman partner leading the firm\u2019s investigation.<\/p>\n

If you invested in ImmunityBio and have substantial losses, or have knowledge that may assist the firm\u2019s investigation, submit your losses now<\/a> \u00bb<\/p>\n

If you\u2019d like more information and answers to frequently asked questions about the ImmunityBio case and the firm\u2019s investigation, read more<\/a> \u00bb<\/a><\/p>\n

\n Whistleblowers: <\/strong>Persons with non-public information regarding ImmunityBio should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895<\/strong> or email IBRX@hbsslaw.com<\/a>.<\/p>\n

\n About Hagens Berman<\/a>
\n
Hagens Berman is a global plaintiffs\u2019 rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman\u2019s team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at\u00a0hbsslaw.com<\/a>. Follow the firm for updates and news at\u00a0@ClassActionLaw<\/a>.<\/p>\n

\n Contact: <\/u>
\n
Reed Kathrein, 844-916-0895<\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

IBRX Investors with Losses Encouraged to Contact the Firm Before May 26th Deadline SAN FRANCISCO, May 25, 2026 (GLOBE NEWSWIRE) — ImmunityBio, Inc. (NASDAQ: IBRX) faces a securities class action lawsuit which seeks to represent investors who purchased or otherwise acquired ImmunityBio securities between January 19, 2026 and March 24, 2026. The lawsuit follows news that the FDA sent a warning letter to the company concerning claims made by its executive chairman and Chief Scientific and Medical Officer (Dr. Patrick Soon-Shiong) regarding ImmunityBio\u2019s lead biologic product (Anktiva), which the FDA said were misleading efficacy claims. This news drove the price of ImmunityBio shares down over 21% on March 24, 2026. The developments have prompted national shareholders rights firm Hagens Berman … <\/p>\n

Continue reading “ImmunityBio (IBRX) Facing Lawsuit After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost — HBSS”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-966553","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nImmunityBio (IBRX) Facing Lawsuit After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost - HBSS - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/immunitybio-ibrx-facing-lawsuit-after-fda-flags-misleading-cancer-claims-shares-plunge-21-2b-market-cap-lost-hbss-3\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ImmunityBio (IBRX) Facing Lawsuit After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost - HBSS - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"IBRX Investors with Losses Encouraged to Contact the Firm Before May 26th Deadline SAN FRANCISCO, May 25, 2026 (GLOBE NEWSWIRE) — ImmunityBio, Inc. (NASDAQ: IBRX) faces a securities class action lawsuit which seeks to represent investors who purchased or otherwise acquired ImmunityBio securities between January 19, 2026 and March 24, 2026. The lawsuit follows news that the FDA sent a warning letter to the company concerning claims made by its executive chairman and Chief Scientific and Medical Officer (Dr. Patrick Soon-Shiong) regarding ImmunityBio\u2019s lead biologic product (Anktiva), which the FDA said were misleading efficacy claims. This news drove the price of ImmunityBio shares down over 21% on March 24, 2026. The developments have prompted national shareholders rights firm Hagens Berman … Continue reading "ImmunityBio (IBRX) Facing Lawsuit After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost — HBSS"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/immunitybio-ibrx-facing-lawsuit-after-fda-flags-misleading-cancer-claims-shares-plunge-21-2b-market-cap-lost-hbss-3\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-25T15:08:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyNjAzNiM3NjE5NzcwIzIwMTg1MzI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunitybio-ibrx-facing-lawsuit-after-fda-flags-misleading-cancer-claims-shares-plunge-21-2b-market-cap-lost-hbss-3\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunitybio-ibrx-facing-lawsuit-after-fda-flags-misleading-cancer-claims-shares-plunge-21-2b-market-cap-lost-hbss-3\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"ImmunityBio (IBRX) Facing Lawsuit After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost — HBSS\",\"datePublished\":\"2026-05-25T15:08:21+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunitybio-ibrx-facing-lawsuit-after-fda-flags-misleading-cancer-claims-shares-plunge-21-2b-market-cap-lost-hbss-3\\\/\"},\"wordCount\":795,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunitybio-ibrx-facing-lawsuit-after-fda-flags-misleading-cancer-claims-shares-plunge-21-2b-market-cap-lost-hbss-3\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcyNjAzNiM3NjE5NzcwIzIwMTg1MzI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunitybio-ibrx-facing-lawsuit-after-fda-flags-misleading-cancer-claims-shares-plunge-21-2b-market-cap-lost-hbss-3\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunitybio-ibrx-facing-lawsuit-after-fda-flags-misleading-cancer-claims-shares-plunge-21-2b-market-cap-lost-hbss-3\\\/\",\"name\":\"ImmunityBio (IBRX) Facing Lawsuit After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost - HBSS - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunitybio-ibrx-facing-lawsuit-after-fda-flags-misleading-cancer-claims-shares-plunge-21-2b-market-cap-lost-hbss-3\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunitybio-ibrx-facing-lawsuit-after-fda-flags-misleading-cancer-claims-shares-plunge-21-2b-market-cap-lost-hbss-3\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcyNjAzNiM3NjE5NzcwIzIwMTg1MzI=\",\"datePublished\":\"2026-05-25T15:08:21+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunitybio-ibrx-facing-lawsuit-after-fda-flags-misleading-cancer-claims-shares-plunge-21-2b-market-cap-lost-hbss-3\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunitybio-ibrx-facing-lawsuit-after-fda-flags-misleading-cancer-claims-shares-plunge-21-2b-market-cap-lost-hbss-3\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunitybio-ibrx-facing-lawsuit-after-fda-flags-misleading-cancer-claims-shares-plunge-21-2b-market-cap-lost-hbss-3\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcyNjAzNiM3NjE5NzcwIzIwMTg1MzI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcyNjAzNiM3NjE5NzcwIzIwMTg1MzI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunitybio-ibrx-facing-lawsuit-after-fda-flags-misleading-cancer-claims-shares-plunge-21-2b-market-cap-lost-hbss-3\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ImmunityBio (IBRX) Facing Lawsuit After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost — HBSS\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ImmunityBio (IBRX) Facing Lawsuit After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost - HBSS - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/immunitybio-ibrx-facing-lawsuit-after-fda-flags-misleading-cancer-claims-shares-plunge-21-2b-market-cap-lost-hbss-3\/","og_locale":"en_US","og_type":"article","og_title":"ImmunityBio (IBRX) Facing Lawsuit After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost - HBSS - Market Newsdesk","og_description":"IBRX Investors with Losses Encouraged to Contact the Firm Before May 26th Deadline SAN FRANCISCO, May 25, 2026 (GLOBE NEWSWIRE) — ImmunityBio, Inc. (NASDAQ: IBRX) faces a securities class action lawsuit which seeks to represent investors who purchased or otherwise acquired ImmunityBio securities between January 19, 2026 and March 24, 2026. The lawsuit follows news that the FDA sent a warning letter to the company concerning claims made by its executive chairman and Chief Scientific and Medical Officer (Dr. Patrick Soon-Shiong) regarding ImmunityBio\u2019s lead biologic product (Anktiva), which the FDA said were misleading efficacy claims. This news drove the price of ImmunityBio shares down over 21% on March 24, 2026. The developments have prompted national shareholders rights firm Hagens Berman … Continue reading \"ImmunityBio (IBRX) Facing Lawsuit After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost — HBSS\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/immunitybio-ibrx-facing-lawsuit-after-fda-flags-misleading-cancer-claims-shares-plunge-21-2b-market-cap-lost-hbss-3\/","og_site_name":"Market Newsdesk","article_published_time":"2026-05-25T15:08:21+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyNjAzNiM3NjE5NzcwIzIwMTg1MzI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunitybio-ibrx-facing-lawsuit-after-fda-flags-misleading-cancer-claims-shares-plunge-21-2b-market-cap-lost-hbss-3\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunitybio-ibrx-facing-lawsuit-after-fda-flags-misleading-cancer-claims-shares-plunge-21-2b-market-cap-lost-hbss-3\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"ImmunityBio (IBRX) Facing Lawsuit After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost — HBSS","datePublished":"2026-05-25T15:08:21+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunitybio-ibrx-facing-lawsuit-after-fda-flags-misleading-cancer-claims-shares-plunge-21-2b-market-cap-lost-hbss-3\/"},"wordCount":795,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunitybio-ibrx-facing-lawsuit-after-fda-flags-misleading-cancer-claims-shares-plunge-21-2b-market-cap-lost-hbss-3\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyNjAzNiM3NjE5NzcwIzIwMTg1MzI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunitybio-ibrx-facing-lawsuit-after-fda-flags-misleading-cancer-claims-shares-plunge-21-2b-market-cap-lost-hbss-3\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/immunitybio-ibrx-facing-lawsuit-after-fda-flags-misleading-cancer-claims-shares-plunge-21-2b-market-cap-lost-hbss-3\/","name":"ImmunityBio (IBRX) Facing Lawsuit After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost - HBSS - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunitybio-ibrx-facing-lawsuit-after-fda-flags-misleading-cancer-claims-shares-plunge-21-2b-market-cap-lost-hbss-3\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunitybio-ibrx-facing-lawsuit-after-fda-flags-misleading-cancer-claims-shares-plunge-21-2b-market-cap-lost-hbss-3\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyNjAzNiM3NjE5NzcwIzIwMTg1MzI=","datePublished":"2026-05-25T15:08:21+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunitybio-ibrx-facing-lawsuit-after-fda-flags-misleading-cancer-claims-shares-plunge-21-2b-market-cap-lost-hbss-3\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/immunitybio-ibrx-facing-lawsuit-after-fda-flags-misleading-cancer-claims-shares-plunge-21-2b-market-cap-lost-hbss-3\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunitybio-ibrx-facing-lawsuit-after-fda-flags-misleading-cancer-claims-shares-plunge-21-2b-market-cap-lost-hbss-3\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyNjAzNiM3NjE5NzcwIzIwMTg1MzI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyNjAzNiM3NjE5NzcwIzIwMTg1MzI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunitybio-ibrx-facing-lawsuit-after-fda-flags-misleading-cancer-claims-shares-plunge-21-2b-market-cap-lost-hbss-3\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"ImmunityBio (IBRX) Facing Lawsuit After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost — HBSS"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/966553","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=966553"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/966553\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=966553"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=966553"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=966553"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}